• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Chronic Pain - Pipeline Review, H2 2012 Product Image

Chronic Pain - Pipeline Review, H2 2012

  • Published: October 2012
  • 250 pages
  • Global Markets Direct

Chronic Pain – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Chronic Pain - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Chronic Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Pain. Chronic Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chronic Pain.
- A review of the Chronic Pain products under development by companies and universities/research institutes based on information derived READ MORE >

2
List of Tables 7
List of Figures 9
Introduction 10
REPORT COVERAGE 10
Chronic Pain Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Chronic Pain 12
Chronic Pain Therapeutics under Development by Companies 14
Chronic Pain Therapeutics under Investigation by Universities/Institutes 19
Late Stage Products 20
Comparative Analysis 20
Mid Clinical Stage Products 21
Comparative Analysis 21
Early Clinical Stage Products 22
Comparative Analysis 22
Discovery and Pre-Clinical Stage Products 23
Comparative Analysis 23
Chronic Pain Therapeutics – Products under Development by Companies 24
Chronic Pain Therapeutics – Products under Investigation by Universities/Institutes 29
Companies Involved in Chronic Pain Therapeutics Development 30
DURECT Corporation 30
Abbott Laboratories 31
AlphaRx, Inc. 32
BioDelivery Sciences International, Inc. 33
Nektar Therapeutics 34
Endo Pharmaceuticals Holdings Inc. 35
Daiichi Sankyo Company, Ltd 36
BioLineRx, Ltd. 37
Zogenix, Inc. 38
A.P. Pharma, Inc. 39
Cephalon, Inc. 40
Daewoong Pharmaceutical Co., Ltd. 41
Esteve Group 42
Glenmark Pharmaceuticals Ltd. 43
Nippon Shinyaku Co., Ltd. 44
Pain Therapeutics, Inc. 45
Pfizer Inc. 46
Purdue Pharma L.P. 47
Zosano Pharma, Inc. 48
Collegium Pharmaceutical, Inc. 49
Alchemia Limited 50
Benitec Ltd. 51
ACADIA Pharmaceuticals Inc. 52
Elite Pharmaceuticals, Inc. 53
CombinatoRx, Incorporated 54
Titan Pharmaceuticals, Inc. 55
POZEN Inc. 56
Theravance, Inc. 57
Orexo AB 58
BioAlliance Pharma SA 59
Labtec GmbH 60
Debiopharm Group 61
Advinus Therapeutics Pvt. Ltd. 62
Chromocell Corporation 63
Immupharma Plc 64
Phosphagenics Limited 65
Neorphys 66
BIOALVO S.A. 67
CoLucid Pharmaceuticals, Inc. 68
Trevena, Inc. 69
QRxPharma Limited 70
Cara Therapeutics, Inc. 71
Xenome Ltd. 72
Antibe Therapeutics, Inc. 73
TheraQuest Biosciences, LLC 74
Afferent Pharmaceuticals, Inc. 75
RaQualia Pharma Inc. 76
Cytogel Pharma, LLC 77
Chronic Pain – Therapeutics Assessment 78
Assessment by Monotherapy Products 78
Assessment by Combination Products 79
Assessment by Route of Administration 80
Assessment by Molecule Type 82
Drug Profiles 85
hydrocodone bitartrate - Drug Profile 85
celecoxib - Drug Profile 87
PTI-202 - Drug Profile 89
sufentanil - Drug Profile 90
CRx-170 - Drug Profile 92
hydromorphone hydrochloride - Drug Profile 94
hydrocodone bitartrate - Drug Profile 95
NEO-1528 - Drug Profile 96
Debio-0827 - Drug Profile 97
ELI-216 - Drug Profile 98
fentanyl citrate - Drug Profile 99
DWJ-208 - Drug Profile 100
BLV-0704 - Drug Profile 101
Vicodin CR - Drug Profile 102
tapentadol hydrochloride ER - Drug Profile 104
tapentadol hydrochloride ER - Drug Profile 107
bupivacaine - Drug Profile 110
hydrocodone bitartrate - Drug Profile 112
ALO-02 - Drug Profile 113
buprenorphine hydrochloride - Drug Profile 115
PTI-721 - Drug Profile 116
buprenorphine hydrochloride - Drug Profile 117
oxycodone - Drug Profile 119
PA-65020 - Drug Profile 121
morphine sulfate + oxycodone hydrochloride CR - Drug Profile 122
AGN-XX/YY - Drug Profile 124
GRT-6005 - Drug Profile 125
fentanyl - Drug Profile 126
Z-160 - Drug Profile 127
meloxicam - Drug Profile 128
hydrocodone bitartrate ER - Drug Profile 129
tramadol hydrochloride - Drug Profile 131
NKTR-181 - Drug Profile 132
buprenorphine hydrochloride - Drug Profile 134
oxymorphone hydrochloride - Drug Profile 136
Xen-2174 - Drug Profile 137
sufentanil - Drug Profile 139
N-type Calcium Channel Blockers - Drug Profile 141
T-Type Calcium Channels Blockers - Drug Profile 142
P2X3 Targeted Program - Drug Profile 143
IPP-102199 - Drug Profile 144
onabotulinumtoxinA - Drug Profile 145
apremilast - Drug Profile 146
fluoxetine - Drug Profile 147
esketamine - Drug Profile 149
K-Opioid Receptor Biased Ligand Program - Drug Profile 150
RQ-00000008 - Drug Profile 151
GBR-900 - Drug Profile 152
CR-701 - Drug Profile 153
NCE-1 - Drug Profile 154
NCE-2 - Drug Profile 155
NCE-3 - Drug Profile 156
DS-5565 - Drug Profile 157
Opioid Program - Drug Profile 158
tramadol hydrochloride - Drug Profile 159
oxymorphone hydrochloride - Drug Profile 161
PF-05089771 - Drug Profile 163
buprenorphine hydrochloride - Drug Profile 165
AF-220 - Drug Profile 166
ARX-8203 - Drug Profile 167
CNV-2197944 - Drug Profile 169
Mu (MOR) - Drug Profile 171
HZN-602 - Drug Profile 172
REC-1100 - Drug Profile 173
Cav2.2 Channel Blocker - Drug Profile 174
Nav Blocker - Drug Profile 175
hydrocodone bitartrate - Drug Profile 176
THA-903 - Drug Profile 177
Conjugated Stigmine Program - Drug Profile 178
methadone hydrochloride - Drug Profile 180
BL-7050 - Drug Profile 182
Oral CR-845 - Drug Profile 183
Cyt-1010 - Drug Profile 185
ddRNAi Program For Cancer-Associated Pain - Drug Profile 187
tebanicline tosylate - Drug Profile 189
NaV1.7 Pain Relief Program - Drug Profile 191
GRT-6006 - Drug Profile 192
ATB-346 - Drug Profile 193
Target 1 For Pain - Drug Profile 194
ER-Beta Program - Drug Profile 195
Drug Targeting Kinase 1 - Drug Profile 196
Drug Targeting Enzyme 1 - Drug Profile 197
E-52862 - Drug Profile 198
Alpha Adrenergic Agonist Program - Drug Profile 199
FY-101C - Drug Profile 200
GPCR-1 - Drug Profile 201
GPCR-2 - Drug Profile 202
RQ-0000007 - Drug Profile 203
fentanyl ZP Patch - Drug Profile 205
AYX-1 - Drug Profile 206
d-Methadone - Drug Profile 207
Chronic Pain Therapeutics – Drug Profile Updates 208
Chronic Pain Therapeutics – Discontinued Products 231
Chronic Pain Therapeutics - Dormant Products 232
Chronic Pain – Product Development Milestones 236
Featured News & Press Releases 236
Appendix 243
Methodology 243
Coverage 243
Secondary Research 243
Primary Research 243
Expert Panel Validation 243
Contact Us 244
Disclaimer 244

List of Tables
Number of Products Under Development for Chronic Pain, H2 2012 18
Products under Development for Chronic Pain – Comparative Analysis, H2 2012 19
Number of Products under Development by Companies, H2 2012 21
Number of Products under Development by Companies, H2 2012 (Contd..1) 22
Number of Products under Development by Companies, H2 2012 (Contd..2) 23
Number of Products under Development by Companies, H2 2012 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H2 2012 25
Comparative Analysis by Late Stage Development, H2 2012 26
Comparative Analysis by Mid Clinical Stage Development, H2 2012 27
Comparative Analysis by Early Clinical Stage Development, H2 2012 28
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 29
Products under Development by Companies, H2 2012 30
Products under Development by Companies, H2 2012 (Contd..1) 31
Products under Development by Companies, H2 2012 (Contd..2) 32
Products under Development by Companies, H2 2012 (Contd..3) 33
Products under Development by Companies, H2 2012 (Contd..4) 34
Products under Investigation by Universities/Institutes, H2 2012 35
DURECT Corporation, H2 2012 36
Abbott Laboratories, H2 2012 37
AlphaRx, Inc., H2 2012 38
BioDelivery Sciences International, Inc., H2 2012 39
Nektar Therapeutics, H2 2012 40
Endo Pharmaceuticals Holdings Inc., H2 2012 41
Daiichi Sankyo Company, Ltd, H2 2012 42
BioLineRx, Ltd., H2 2012 43
Zogenix, Inc., H2 2012 44
A.P. Pharma, Inc., H2 2012 45
Cephalon, Inc., H2 2012 46
Daewoong Pharmaceutical Co., Ltd., H2 2012 47
Esteve Group, H2 2012 48
Glenmark Pharmaceuticals Ltd., H2 2012 49
Nippon Shinyaku Co., Ltd., H2 2012 50
Pain Therapeutics, Inc., H2 2012 51
Pfizer Inc., H2 2012 52
Purdue Pharma L.P., H2 2012 53
Zosano Pharma, Inc., H2 2012 54
Collegium Pharmaceutical, Inc., H2 2012 55
Alchemia Limited, H2 2012 56
Benitec Ltd., H2 2012 57
ACADIA Pharmaceuticals Inc., H2 2012 58
Elite Pharmaceuticals, Inc., H2 2012 59
CombinatoRx, Incorporated, H2 2012 60
Titan Pharmaceuticals, Inc., H2 2012 61
POZEN Inc., H2 2012 62
Theravance, Inc., H2 2012 63
Orexo AB, H2 2012 64
BioAlliance Pharma SA, H2 2012 65
Labtec GmbH, H2 2012 66
Debiopharm Group, H2 2012 67
Advinus Therapeutics Pvt. Ltd., H2 2012 68
Chromocell Corporation, H2 2012 69
Immupharma Plc, H2 2012 70
Phosphagenics Limited, H2 2012 71
Neorphys, H2 2012 72
BIOALVO S.A., H2 2012 73
CoLucid Pharmaceuticals, Inc., H2 2012 74
Trevena, Inc., H2 2012 75
QRxPharma Limited, H2 2012 76
Cara Therapeutics, Inc., H2 2012 77
Xenome Ltd., H2 2012 78
Antibe Therapeutics, Inc., H2 2012 79
TheraQuest Biosciences, LLC, H2 2012 80
Afferent Pharmaceuticals, Inc., H2 2012 81
RaQualia Pharma Inc., H2 2012 82
Cytogel Pharma, LLC, H2 2012 83
Assessment by Monotherapy Products, H2 2012 84
Assessment by Combination Products, H2 2012 85
Assessment by Stage and Route of Administration, H2 2012 87
Assessment by Stage and Molecule Type, H2 2012 90
Chronic Pain Therapeutics – Drug Profile Updates 214
Chronic Pain Therapeutics – Discontinued Products 237
Chronic Pain Therapeutics – Dormant Products 238
Chronic Pain Therapeutics – Dormant Products (Contd..1) 239
Chronic Pain Therapeutics – Dormant Products (Contd..2) 240
Chronic Pain Therapeutics – Dormant Products (Contd..3) 241

List of Figures
Number of Products under Development for Chronic Pain, H2 2012 18
Products under Development for Chronic Pain – Comparative Analysis, H2 2012 19
Products under Development by Companies, H2 2012 20
Products under Investigation by Universities/Institutes, H2 2012 25
Late Stage Products, H2 2012 26
Mid Clinical Stage Products, H2 2012 27
Early Clinical Stage Products, H2 2012 28
Discovery and Pre-Clinical Stage Products, H2 2012 29
Assessment by Monotherapy Products, H2 2012 84
Assessment by Combination Products, H2 2012 85
Assessment by Route of Administration, H2 2012 86
Assessment by Stage and Route of Administration, H2 2012 87
Assessment by Molecule Type, H2 2012 88
Assessment by Stage and Molecule Type, H2 2012 89

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos